• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    CRYSTALLINE FORMS 1 AND 2, PHARMACEUTICAL COMPOSITION, USE OF CRYSTALLINE 1 FOR THE TREATMENT OF A DISEASE STATABLE BY ALK INHIBITION AND PROCESS FOR THE PREPARATION OF N- [5- (3,5-DIFLUORO-BENZIL) -1H- INDAZOL-3-IL] -4- (4-METHYL-PIPERAZIN-1-IL) -2- (TETRA-HYDRO-PYRAN-4-ILAMINE) - BENZAMIDE. The invention relates to a process for the preparation of N- [5- (3,5-difluoro-benzyl) -1H-indazol-3-yl] -4- (4-methyl-piperazin-1-yl) - 2- (tetrahydro-pyran-4-ylamino) -benzamide. New solid forms of this compound, its use in the treatment of diseases caused by the unregulated activity of protein kinase and pharmaceutical compositions that contain them are also the object of the present invention.
    公开号:BR112014028841B1
    申请号:R112014028841-0
    申请日:2013-05-22
    公开日:2021-01-12
    发明作者:Natale Alvaro Barbugian；Romualdo Forino；Tiziano Fumagalli；Paolo Orsini
    申请人:Nerviano Medical Sciences S.R.L.；
    IPC主号:
    专利说明:

    [001] The present invention relates to a process for the preparation of N- [5- (3,5-difluoro-benzyl) -1H-indazol-3-yl] -4- (4-methyl-piperazin-1 -yl) -2- (tetrahydro-pyran-4-ylamino) -benzamide. New solid forms of this compound, its use in the treatment of diseases caused by the unregulated activity of protein kinase and the pharmaceutical compositions that contain them are also the subject of the present invention.
    [002] The malfunction of protein kinases (PKs) is the hallmark of numerous diseases. A large part of the oncogenes and proto-oncogenes involved in human cancers code for PKs. Enhanced PK activities are also implicated in many non-malignant diseases, such as benign prostatic hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, proliferation of vascular smooth cells associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and stenosis and post-surgical restenosis.
    [003] PKs are also implicated in inflammatory conditions and in the multiplication of viruses and parasites. PKs can also play an important role in the pathogenesis and development of neurodegenerative disorders.
    [004] For a general reference to malfunctioning or deregulated PKs see, for example, Current Opinion in Chemical Biology 1999, 3, 459-465; Nature Rev. Drug Discov. 2002; Carcinogenesis 2008, 29, 1087-1091.
    [005] A subset of PK is a group of membrane receptors with intrinsic protein tyrosine kinase (RPTK) activity. After the attachment of growth factors, RPTKs become activated and phosphorylate and a series of substrates in the cytoplasm. Through this mechanism, they can transduce intracellular signaling for proliferation, differentiation or other biological changes. Structural anomalies, overexpression and activation of RTPKs are frequently seen in human tumors, which suggests that the ignition constitutive of the signal transduction leading to cell proliferation may result in malignant transformation. Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that belongs to the insulin receptor subfamily of RTKs: the ALK gene is located on chromosome 2 and is expressed mainly in neuronal cells, especially during development. The ALK gene is involved in a chromosomal translocation balanced with the nucleophosmin (NPM) gene on chromosome 5 in a large subset of anaplastic large cell lymphomas (ALCL). In ALK + ALCL, as a result of translocation, the ubiquitous NPM promoter drives an ectopic expression of the fusion protein in which the NPM portion dimerizes and the ALK kinase domain undergoes autophosphorylation and becomes constitutively active.
    [006] Many data in the literature have shown that the NPM-ALK fusion protein has a strong oncogenic potential and its ectopic expression is responsible for cell transformation. In addition, the constitutive expression of human NPM-ALK in rat T-cell lymphocytes is sufficient for the development of lymphoid neoplasia in transgenic animals with a short latency period.
    [007] ALCL is a defined disease, characterized by the surface expression of the CD30 antigen (Ki-1), and is responsible for 2% of adults and 13% of pediatric non-Hodgkin's lymphomas, which predominantly affects young male patients . ALK + ALCL accounts for 70% of all ALCLs and is an aggressive disease with systemic signs and frequent extranodal involvement (bone marrow, skin, bones, mol tissues).
    [008] About 15-20% of ALCLs that express ALK were found to support a different chromosomal translocation, involving the cytoplasmic portion of ALK, with different N-terminal portions, all resulting in the constitutive activation of the ALK kinase domain.
    [009] In addition, cell lines established from solid tumors of ectodermal origin such as melanomas, breast carcinomas, as well as neuroblastomas, glioblastomas, Ewings sarcoma, retinoblastomas, have been found to express the ALK receptor.
    [0010] In conclusion, what interferes with ALK signaling probably represents a specific and effective way to block tumor cell proliferation in ALCL and possibly other indications.
    [0011] International patent application W02009 / 013126 (Nerviano Medical Sciences Srl.) Describes and claims the free base form of N- [5- (3,5-difluoro-benzyl) -1H-indazol-3-yl] -4- (4-methyl-piperazin-1-yl) -2- (tetrahydro-pyran-4-ylamino) benzamide, which has the formula (1),
    and reports that the compound is active as a kinase inhibitor, more particularly as an ALK inhibitor, and is thus useful in the treatment of a variety of cancers and cell proliferative diseases.
    [0012] The preparations of this compound are described in example 2 (step i ') and in example 7 of the above-mentioned patent application.
    [0013] The known preparation of the compound of formula (I), as described in example 2 (step i ') of the patent application referred to above essentially comprises the addition of a solution of 5- (3,5-difluoro- benzyl) -1H-indazol-3-ylamine to acyl chloride 4- (4-methyl-piperazin-1-yl) -2 - [(tetrahydro-pyran-4-yl) - (2,2,2- trifluoro-acetyl) -amino] -benzoic acid and then deprotecting with an organic base at an elevated temperature the compound obtained to give the desired amide of formula (I), after purification by column chromatography and crystallization.
    [0014] The known preparation of the compound of formula (I) as described in example 7 of the above-mentioned patent application essentially comprises the reaction of 2-amino-N- [5- (3,5-difluoro-benzyl) -1H-indazol-3-yl] -4- (4-methyl-piperazin-1-yl) -benzamide with tetrahydro-pyran-4-one in the presence of trifluoroacetic acid and tetramethylammonium triacetoxyborohydride to give the amide formula (I) after purification by column chromatography.
    [0015] In this regard, we have now surprisingly found that the compound of formula (I) can be advantageously prepared through a process that allows to obtain the desired product in an industrially advantageous and highly reproducible manner, with a high degree of purity, with characteristics suitable for administration to humans and at a reduced cost. In addition, the new process is more suitable for application in large-scale production. Finally, said compound is obtained in defined solid forms.
    Accordingly, a process for the preparation of the compound of formula (I) as defined above is a first object of the present invention, which process comprises: a) the addition of a stoichiometric form of the acyl chloride with the formula (II):
    to the indazol-3-ylamine of formula (111):
    blocking the addition when the indazol-3-yl-amine of formula (III) is completely reacted; b) unprotect the compound resulting from formula (IV) under mild basic conditions:
    to obtain the desired compound of formula (I), which is isolated in amorphous form; the desired crystalline form is then obtained either: c1) treating the resulting amorphous compound of formula (I) with a mixture of ethanol and water, in the presence of seeds, to give the desired compound of formula (I) in crystalline form 1; or c2) treating the resulting amorphous compound of formula (I) with a mixture of ethanol and water, to give the desired compound of formula (I) in crystalline form 2, and optionally; d) converting the resulting compound obtained in step b), step c1) or step c2) to a pharmaceutically acceptable salt.
    [0017] The new process allows to obtain a compound of formula (I) with high purity, without chromatographic purifications and controlling the solid form.
    [0018] Due to the order of addition and the stoichiometric addition of the acyl derivative of formula (II) to the indazolylamine derivative of formula (III), followed by an isolation work with the appropriate solvent mixture, the protected intermediate of formula ( IV) obtained in step a) is purer than in the previous process. As a matter of fact, this new procedure considerably reduces the formation of impurities, such as, for example, the formation of unwanted regioisomers and double addition products, thus avoiding the need to purify the product thus obtained from formula (IV) through the use of chromatography columns, not suitable for large-scale preparations because of the time and costs associated with this procedure.
    [0019] In addition, in step b), transforming the product of formula (IV) into the final product of formula (I), the mild deprotection conditions, consisting of aqueous hydrolysis at low temperature with inorganic bases, prevent the formation of observed by-products in the previous procedure due to the high temperature treatment with organic bases in methanol.
    [0020] Finally in step c1) or step c2) the compound of formula (I), obtained first in an amorphous form, is then converted, respectively, to crystalline form 1 by sowing or to crystalline form 2 by treatment with suitable solvents. In the previous process, at this point, the purity of the compound and the isolation procedures by insolubilization and / or chromatographic purification were such to avoid the conversion of any crystalline form 1 or crystalline form 2.
    [0021] According to step a), the compound of formula (II) is suspended in solvents, such as THF or DCM, preferably it is suspended in dry DCM, and then the suspension is added slowly and gradually to a solution of the compound of formula (III) in pyridine.
    [0022] Preferably, the reaction is carried out at a temperature between -20 ° C and -40 ° C, preferably operating at a temperature between -30 ° C and -40 ° C.
    [0023] At the end of the reaction, the solvents are evaporated and the residue treated with solvents such as DCM, MTBE, MeOH in a pre-defined ratio between 1/1/1 and 30/30/1, preferably, the treatment is done with in the proportions of DCM / MTBE / MeOH between 8/8/1 and 30/30/1, to obtain the precipitation of a pure compound of formula (IV).
    [0024] According to step b), deprotection of the compound of formula (IV) can be carried out by mild basic conditions, such as methanolic / aqueous or aqueous alkaline carbonates or hydroxides, preferably a solution of K2CO3 in water / methanol is used.
    [0025] Preferably, the reaction is carried out at a temperature between 20 ° C and 5 ° C, preferably operating at about 10 ° C.
    [0026] The desired compound of formula (I) is then isolated in amorphous form by dripping in water at a temperature between 5 ° C and 25 ° C, preferably at a temperature between 5 ° C and 10 ° C.
    [0027] According to step c1) the amorphous compound of formula (I) is treated first by heating ethanol to reflux and distilling part of the solvent, then with water and seeds of crystalline form 1 at a temperature between 10 ° C and 30 ° C, preferably at a temperature between 20 ° C and 25 ° C. The compound obtained of formula (I) is in crystalline form 1.
    [0028] According to step c2) the compound obtained according to step b) is treated sequentially with ethanol, at a temperature between 10 ° C and 30 ° C, preferably at a temperature between 20 ° C and 25 ° C, and then with water at a temperature between 10 ° C and 30 ° C, preferably at a temperature between 20 ° C and 25 ° C. The compound obtained of formula (I) is in crystalline form 2.
    [0029] The starting compounds and reagents employed in the process of the present invention are known compounds or can be obtained from known compounds using well-known methods. In particular, the preparation of the compounds of formula (II) and (III), as defined above is described in the patent application cited above.
    [0030] No solid, amorphous or crystalline forms are mentioned in example 2 (step i ') and in example 7 of the patent application mentioned above. The present inventors have studied and found that the compound of formula (I), prepared as described in example 2 (step i ') is a crystal solvate which is referred to hereinafter as crystalline form 3 for convenience; the compound of formula (I), prepared as described in example 7, is amorphous and hereinafter referred to as amorphous form.
    [0031] Furthermore, the present inventors have found that the compound of formula (I) prepared as described in example 1, step b) of the present application is amorphous; the compound of formula (I) prepared as described in example 1, step c1) of the present patent application is a crystal which hereinafter is referred to as crystalline form 1; finally, the compound of formula (I) prepared as described in example 1, step c2) of the present patent application is a crystal which hereinafter is referred to as crystalline form 2.
    [0032] Then, in a further aspect, the present invention relates to new and stable crystalline forms of the compound of formula (I), that is, crystalline form 1 and crystalline form 2, prepared by the process described above.
    [0033] Crystalline form 3 is a solvate with EtOAc and n-hexane and is not suitable for administration to humans due to the presence of unacceptable amounts of solvents; the amorphous form is a hygroscopic solid, which is less suitable for the development of an oral formulation.
    [0034] Moisture absorption is a significant concern for pharmaceutical powders. Moisture has been shown to have a significant impact, for example, on the physical, chemical and manufacturing properties of drugs, excipients and formulations. It is also a key factor in making decisions related to packaging, storage, handling and shelf life, and successful development requires a solid understanding of hygroscopic properties.
    [0035] For example, the conversion from an anhydrous form to a hydrate form can be observed when the relative humidity is higher than a critical level and the moisture content increases rapidly in the solid. This has an impact not only on the physical and pharmaceutical properties of the drug per se, but also on its biopharmaceutical perspective. In addition, it is well known that hydrate forms generally tend to be less soluble with respect to a homologous anhydrous form, with potential negative effect also on the dissolution rate properties of the active compound per se and on its profile. absorption through the gastrointestinal tract. In the same way, the conversion from an amorphous to a crystalline form can be observed in the presence of moisture, with potential disadvantages in terms of physical stability. The amorphous active drug substance, if deliquescent, can, for example, absorb relatively large amounts of water from the atmosphere, until it dissolves at the same time that its chemical stability can be affected since the amorphous structure, being thermodynamically activated, it is more prone to chemical degradation and chemical interaction with other chemical species. Thus, the performance and effectiveness of both the formulation and the active ingredient can be significantly altered.
    Therefore, there is a need in therapy for solid forms of the compound of formula (I) suitable for administration to humans that do not contain unacceptable amounts of residual solvents and have low hygroscopicity, as well as good biopharmaceutical and reproducible properties to allow safer and more effective oral administration.
    [0037] The present inventors solved the technical problem described above, providing new crystalline forms of the compound of formula (I) being suitable for administration to humans and having improved physicochemical properties. In fact, the new crystalline forms do not retain solvents and are less hygroscopic than the amorphous form, in addition to having all the other advantages, in specific therapeutic advantages, exhibited by the known forms. BRIEF DESCRIPTION OF THE DRAWINGS
    [0038] The invention is also illustrated by reference to the accompanying drawings, described below.
    [0039] Figure 1 shows the X-ray diffractograms of crystalline form 3.
    [0040] 2-Theta angles (°) are reported on the x axis, while the intensity (CPS) is reported on the y axis.
    [0041] Figure 2 shows the X-ray diffractograms of the amorphous form.
    [0042] 2-Theta angles (°) are reported on the x axis, while the intensity (CPS) is reported on the y axis.
    [0043] Figure 3 shows the X-ray diffractograms of crystalline form 1.
    [0044] 2-Theta angles (°) are reported on the x axis, while the intensity (CPS) is reported on the y axis.
    [0045] Fig. 4 shows the X-ray diffractograms of crystalline form 2.
    [0046] 2-Theta angles (°) are reported on the x axis, while the intensity (CPS) is reported on the y axis.
    [0047] Figure 5 shows the DSC thermograms of amorphous form, crystalline form 1 and crystalline form 2.
    [0048] The thermogram reports temperature (° C) and time (minutes) on the x axis, while the heat flow (mW) is reported on the y axis.
    [0049] Figure 6 shows the plot of the DVS isotherm of amorphous form, crystalline form 1 and crystalline form 2.
    [0050] The relative humidity values (RH,%) are reported on the x-axis, while change in mass (%) is reported on the y-axis. The curves are related to the sorption step between 0% RH and 90% RH at 25 ° C.
    [0051] Figure 7 shows the 1 H NMR spectrum of crystalline form 1.
    [0052] Chemical deviation (ppm) is reported on the x-axis.
    [0053] Figure 8 shows the 1 H NMR spectrum of crystalline form 3.
    [0054] Chemical deviation (ppm) is reported on the x axis.
    [0055] Crystalline form 3 is characterized by an X-ray diffraction diagram that is substantially the same as the diagram reported in Figure 1, with the intensities of the significant peaks over the 2-theta values (degrees) described in the table 1. In samples that are free of any additional materials (other crystalline forms, excipients), it must be possible to observe the diffraction peaks at about the 2-theta values (degrees) described in table 2.
    [0056] The amorphous form is characterized by an X-ray diffraction diagram that is substantially the same as the diagram reported in Figure 2.
    [0057] Crystalline form 1 is characterized by an X-ray diffraction diagram that is substantially the same as the diagram reported in Figure 3, with the intensities of the significant peaks over the 2-theta (degrees) values described in the table 1. In the samples to be free of any additional materials (other crystalline forms, excipients), it must be possible to observe the diffraction peaks at about 2-theta values (degrees) described in table 3.
    [0058] Crystalline form 2 is characterized by an X-ray diffraction diagram that is substantially the same as the one reported in Figure 4, with the intensities of the significant peaks over the 2-theta (degrees) values described in the table 1. In the samples to be free of any additional materials (other crystalline forms, excipients), it must be possible to observe the diffraction peaks at about 2-theta values (degrees) described in table 4.
    [0059] As an additional aspect, it was found that crystalline form 3 is a high melting point crystalline form of the compound of formula (I) showing solvation with ethyl acetate and n-hexane (PXRD profile: Fig. 1; other references about PXRD are described in table 1).
    [0060] As an additional aspect, it was found that the amorphous form shows a water absorption of 2.5% at 25 ° C / 90% RH which is reversible by decreasing the RH at a constant temperature of 25 ° C (PXRD profile: Figure 2; DSC profile: Figure 5; DVS profile: Figure 6: other references about the PXRD, DSC and DVS profiles are described in table 1).
    [0061] As an additional aspect, it has been found that crystalline form 3 is a high melting point crystalline form of the compound of formula (I) which shows a water absorption of 0.6% at 25 ° C / 90% RH which is less than amorphous and reversible by decreasing RH at a constant temperature of 25 ° C (PXRD profile: Figure 3; DSC profile: Figure 5; DVS profile: Figure 6: other references about the PXRD, DSC and DVS profiles are described in table 1).
    [0062] As an additional aspect, it has been found that crystalline form 2 is a high melting point crystalline form of the compound of formula (I) which shows a water absorption of 0.2% at 25 ° C / 90% RH which is less than amorphous and reversible by decreasing RH at a constant temperature of 25 ° C (PXRD profile: Figure 4; DSC profile: Figure 5; DVS profile: Figure 6: other references about the PXRD, DSC and DVS profiles are described in table 1). TABLE 1 - DESCRIPTION OF THE PROPERTIES OF THE SOLID STATE AND REFERENCES OF FIGURES / TABLE OF THE CRYSTALLINE FORM 3, AMORFA FORM, CRYSTALLINE FORM 1 AND CRYSTALLINE FORM 2 OF THE COMPOUND OF FORMULA (I).
    Note (*): the reported PXRD peaks were selected according to their high intensity among the complete data set.
    [0063] Another object of the invention is to provide a pharmaceutical composition comprising a therapeutically effective amount of crystalline form 1 or crystalline form 2 as defined above, or a pharmaceutically acceptable salt thereof, as an active ingredient and a pharmaceutically acceptable excipient, vehicle or diluent .
    [0064] Crystalline form 1 or crystalline form 2 as defined above, or a pharmaceutically acceptable salt thereof, is rapidly absorbed orally, so it is preferably administered orally. It goes without saying that the compounds of the present invention can be administered by any route of administration, for example, parenteral, topical, rectal and nasal.
    [0065] The compositions of the invention may be in a form suitable for oral use. Examples of these forms are: tablets, hard or mol capsules, aqueous or oily suspensions, emulsions, powders or dispersible granules. The compositions of the invention can also be in a form suitable for topical use. Examples of these forms are: creams, ointments, gels, or aqueous or oily solutions or suspensions. The compositions of the invention may also be in a form suitable for administration by inhalation, such as, for example, finely divided powder or a liquid aerosol. The compositions of the invention can also be in a form suitable for administration by insufflation, such as, for example, finely divided powder. The compositions of the invention may also be in a form suitable for parenteral administration (such as, for example, a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular administration) or as a suppository for rectal dosing.
    [0066] The compositions of the invention can be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art.
    [0067] Thus, compositions intended for oral use may contain one or more additives, such as, for example, dyes, sweeteners, flavorings and preservatives.
    [0068] For example, solid oral forms may contain, together with the active compound, diluents, for example, lactose, dextrose, sucrose, sucrose, mannitol, cellulose, corn starch or potato starch; lubricants, for example, silica, talc, stearic acid, magnesium stearate or calcium stearate, and / or polyethylene glycols; gliding agents, for example, colloidal silicon dioxide; binding agents, for example, starches, gum arabic, methylcellulose gelatin, carboxymethylcellulose or polyvinyl pyrrolidone; disintegrating agents, for example, starch, alginic acid, alginates or sodium starch glycolate; effervescent mixtures; coloring matters; sweeteners; humidifying agents such as lecithin, polysorbates, lauryl sulfates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. These pharmaceutical preparations can be manufactured in a known manner, for example, by means of mixing, granulating, compressing, sugar coating, or film coating processes.
    [0069] Liquid dispersions for oral administration can be, for example, syrups, emulsions and suspensions.
    [0070] As an example, syrups may contain, as a vehicle, sucrose or sucrose with glycerin and / or mannitol and sorbitol.
    [0071] Suspensions and emulsions may contain, as examples of vehicles, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
    [0072] The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, for example, sterile water, olive oil, ethyl oleate, glycols, for example, propylene glycol and, if desired, an adequate amount of lidocaine hydrochloride.
    [0073] Solutions for intravenous injections or infusions may contain, as a vehicle, sterile water or preferably may be in the form of sterile aqueous, isotonic, saline solutions, or may contain propylene glycol as a vehicle.
    [0074] Suppositories may contain, together with the active compound, a pharmaceutically acceptable carrier, for example, cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
    [0075] Another object of the invention is to provide crystalline form 1 or crystalline form 2 as defined above, or a pharmaceutically acceptable salt thereof, for use as a medicament.
    [0076] Another object of the invention is to provide crystalline form 1 or crystalline form 2, as defined above, or a pharmaceutically acceptable salt thereof, either alone or in combination with other therapeutic agents or radiotherapy, for use in the treatment of a disease state treatable by ALK inhibition, such as cancer and cell proliferation disorders.
    [0077] Another object of the invention is to provide a method for treating a mammal, including a human, in need of ALK inhibition, comprising administering to said mammal a therapeutically effective amount of crystalline form 1 or crystalline form 2 as defined above, or a pharmaceutically acceptable salt thereof.
    [0078] Finally, another objective of the invention is to provide the use of crystalline form 1 or crystalline form 2 as defined above, or a pharmaceutically acceptable salt thereof, either alone or in combination with other therapeutic agents or radiotherapy, for the manufacture of a medicine for the treatment of a disease state treatable by ALK inhibition, such as cancer and cell proliferation disorders.
    [0079] The term "treatable disease state" means that the treatment according to the invention provides remission of the disease state, at least the conditions and quality of life of the mammal under treatment are improved.
    [0080] Examples of such disease states are, in particular, different cancers that may include specific types of cancer including carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central nervous system and peripheral, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratocantomas, follicular thyroid cancer and Kaposi's sarcoma.
    [0081] Other preferred disease states are specific types of cancer, such as, but not limited to, breast cancer, lung cancer, colorectal cancer, prostate cancer, ovarian cancer, endometrial cancer, gastric cancer, carcinoma of clear cell kidney cells, uveal melanoma, multiple myeloma, rhabdomyosarcoma, Ewing's sarcoma, Kaposi's sarcoma, and medulloblastoma. Other preferred disease states are ALK + anaplastic large cell lymphoma (ALCL) and possibly other indications in which ALK activity may play a role, such as neuroblastoma, rhabdomyosarcoma, glioblastoma, inflammatory myofibroblastic tumor, and some type of melanoma, breast carcinomas, Ewing's sarcomas, retinoblastomas and non-small cell lung carcinomas (NSCLC).
    [0082] Other preferred disease states are proliferative cell disorders, such as, but not limited to, benign prostatic hyperplasia, familial adenomatous polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis, glomerulonephritis and post-surgical stenosis and restenosis.
    [0083] The term "other therapeutic agents" may include, but is not limited to, anti-hormonal agents, such as anti-estrogens, anti-androgens, aromatase inhibitors, topoisomerase I inhibitors, topoisomerase II inhibitors, agents that target microtubules, platinum-based agents, alkylating agents, DNA-damaging or intercalating agents, anti-neoplastic anti-metabolites, other kinase inhibitors, other anti-angiogenic agents, kinesin inhibitors, therapeutic monoclonal antibodies, mTOR inhibitors , histone deacetylase inhibitors, farnesyl transferase inhibitors and hypoxic response inhibitors.
    [0084] The effective dose of the compound of formula (I), crystalline form 1 or crystalline form 2 as defined above, or a pharmaceutically acceptable salt thereof, may vary according to the disease, severity of the disorder and the condition of the patient being treated. Therefore, the doctor, as always, must define the ideal dose for each patient. In any case, the effective dosage range can be from about 10 mg to about 1 g per dose (calculated as a free base), from 1 to 3 times a day. EXAMPLES
    [0085] The following examples illustrate the invention.
    [0086] Temperatures are measured in degrees Celsius (° C).
    [0087] Unless otherwise indicated, reactions or experiments are carried out at room temperature.
    [0088] Abbreviations: RT: room temperature RH: relative humidity PXRD: X-ray powder diffraction DSC: differential scanning calorimetry DVS: dynamic vapor sorption TGA: thermogravimetric analysis ACN (acetonitrile) EtOAc (ethyl acetate) DCM (dichloromethane) DMA (N, N-dimethylacetamide) DMF (N, N-dimethylformamide) DMSO (dimethylsulfoxide) MTBE (methyl-tert-butyl ether) THF (tetrahydrofuran) TFA (trifluoroacetic acid) Example 1: Preparation of the crystalline form 1 and crystalline form 2 of the compound of formula (I).
    [0089] Scheme 1 below shows the preparation of crystalline form 1 and crystalline form 2 of the compound of formula (1).

    [0090] To a suspension of 4- (4-methylpiperazin-1-yl) -2- [tetrahydro-2H-pyran-4-yl (trifluoroacetyl) amino] benzoic acid trifluoroacetate (3.7 kg, 7 milli ) in dry DCM (36 L) and N, N-dimethylformamide (14 ml), oxalyl chloride (1.78 l, 21 mol) is added. The mixture is stirred for about 1.5 hours and evaporated to the oily residue; Dry DCM is then added and evaporated twice.
    [0091] The acyl chloride of formula (II) is suspended in dry DCM and the suspension is added slowly and gradually to a solution of 5- (3,5-difluoro-benzyl) -1H-indazol-3-ylamine (1 , 6 kg, 6.1 mol) in dry pyridine (16 l) at -40 / -30 ° C. Addition is blocked when 5- (3,5-difluoro-benzyl) -1H-indazol-3-ylamine is completely reacted. After about 1 hour the solvent is evaporated and DCM (55 l), methanol (6.5 l), and MTBE (55 l) are added sequentially. The purified protected compound of formula (IV) is filtered, washed with a 10/10/1 mixture of DCM / MTBE / MeOH and dried under vacuum (3.8 kg).
    [0092] The thus obtained crude N- [5- (3,5-difluorobenzyl) -1H-indazol-3-yl] -4- (4-methyl-piperazin-1-yl) -2 - [(tetra- hydro-pyran-4-yl) -2,2,2-trifluoro-acetyl) -amino] -benzamide, with HPLC purity> 95%, is dissolved in methanol and added with a solution of K2CO3 in water / methanol, to 10 ° C. The solution is filtered and dripped into the water; the amorphous precipitate of N- [5- (3,5-difluorobenzyl) -1H-indazol-3-yl] -4- (piperazin-1-yl-4-methyl) -2- (tetrahydro-pyran-4 - ylamino) -benzamide is filtered, washed with water and dried under vacuum (2.88 kg).
    [0093] 5.5 g of N- [5- (3,5-difluorobenzyl) -1H- indazol-3-yl] -4- (piperazin-1-yl-4-methyl) -2- (tetrahydro - amorphous dry pyran-4-ylamino) -benzamide are suspended in 130 ml of ethanol and heated to reflux for 10 minutes; about 70 ml of ethanol is distilled before cooling to room temperature. 110 ml of water is added and the suspension is seeded with 55 mg of crystalline form 1. The suspension is stirred for about 72 hours with sampling to monitor conversion to crystalline form 1 by DSC. The suspension is then filtered and dried to give 4.3 g of the desired crystalline form 1.
    [0094] N- [5- (3,5-difluorobenzyl) -1H-indazol-3-yl] -4- (4-methyl-piperazin-1-yl) -2- (tetrahydro-pyran-4 -amylamino) -dry amorphous benzamide (2.88 kg) is entrained in about 10 volumes of ethanol to allow conversion to the desired crystalline form 2; 20 volumes of water are then added and the suspension is filtered. The product is finally dried under vacuum thus giving about 2.6 kg of N- [5- (3,5-difluorobenzyl) -1H-indazol-3-yl] -4- (4-methyl-piperazin-1-yl ) -2- (tetrahydro-pyran-4-ylamino) -benzamide (4.6 mol) in the desired crystalline form 2. Example 2: Analytical results by means of X-ray powder diffraction (PXRD)
    [0095] Crystalline form 3, amorphous form, crystalline form 1 and crystalline form 2 of the compound (1), were characterized by X-ray powder diffraction (PXRD) performed using a Thermo / ARL XTRA apparatus, radiating powder samples with a CuKa source (radiation 45 kV, 40 mA, 1.8 kW-Kα1, wavelength À = 1.54060 Angstrom) between 2 ° and 40 ° theta at room temperature.
    [0096] The scan rate was 1.20 ° / min (step 0.020 ° with counting time of 1 second per step).
    [0097] In X-ray diffractograms, the 2-theta diffraction angles are plotted on the horizontal axis (x-axis) and the line intensity on the vertical axis (y-axis).
    [0098] In the paragraphs defining the X-ray powder diffraction peaks for the crystalline forms of the compound of formula (I), the term "about" is used in the expression '... at angles of about 2- theta reported in the table ... 'to indicate that the exact positions of the peaks (that is, the reported 2-theta angle values) should not be considered as absolute values because, as will be appreciated by those skilled in the art, the position The exact spikes may vary slightly from one machine to another, from one sample to another, or as a result of slight variations in the measurement conditions used.
    [0099] It is also appreciated in the previous paragraphs that the amorphous form and the crystalline forms of the compound of formula (I) provide X-ray powder diffraction patterns substantially the same as the X-ray powder diffraction patterns shown in Figures 1, 2, 3 and 4 and has substantially the most prominent peaks in the values of the 2-theta angle shown in tables 1, 2, 3 and 4. It will be appreciated that the use of the term "substantially" in this context, is also intended to indicate that the values of the 2-theta angle of X-ray powder diffraction patterns may vary slightly from one machine to another, from one sample to another or as a result of slight variations in the measurement conditions, so that the Peak positions shown in the figures or indicated in the tables should not again be taken as absolute values.
    [00100] In this regard, it is known in the art that an X-ray powder diffraction pattern can be obtained that has one or more measurement errors depending on the measurement conditions (such as, for example, equipment and / or preparation Sample). In particular, it is generally known that the intensities in an X-ray powder diffraction pattern can vary depending on the measurement conditions and the sample preparation.
    [00101] For example, people skilled in the X-ray powder diffraction technique will realize that the relative intensity of the peaks can be affected by, for example, grains over 30 μm in size and non-unit aspect ratios that can affect sample analysis.
    [00102] The expert will also realize that the reflection position can be affected by the precise height at which the sample is in the diffractometer and the zero calibration of the diffractometer.
    [00103] The planarity of the sample surface can also affect the result.
    [00104] Thus, one skilled in the art will appreciate that the diffraction pattern data presented here should not be considered as absolute (for more information, see "Fundaments of Powder Diffraction and Structural Characterization", Pecharsky and Zavalij, Kluwer Academic Publishers, 2003). Therefore, it should be understood that the amorphous and crystalline forms of the compound of formula (I) described in the present invention are not limited to amorphous and the crystals that provide X-ray powder diffraction patterns identical to powder diffraction patterns X-ray images shown in Figures 1, 2, 3 and 4 and any sample or batch of amorphous or crystalline forms of the compound of formula (I) providing X-ray powder diffraction patterns substantially the same as those shown in Figures 1, 2, 3 and 4 within the scope of the present invention. An expert in the X-ray powder diffraction technique is able to assess the substantial identity of X-ray powder diffraction patterns.
    [00105] Generally, an error in measuring an X-ray powder diffraction angle of a diffractogram is about 2-theta = 0.5 degrees or less (or, more appropriately, about 2-theta = 0, 2 degrees or less) and such a degree of measurement error should be taken into account when considering the X-ray powder diffraction pattern in Figures 1, 2, 3, and 4 and when comparing the patterns or interpreting the positions of the peaks referred to both in the text and in tables 1, 2, 3 and 4.
    [00106] Therefore, where it is said, for example, that the crystalline forms of the compound of formula (1), have an X-ray powder diffraction pattern with at least a specific peak of about 2-theta = 20, 1 degrees (or any of the other angles mentioned), so this can be interpreted as being 2-theta = 20.1 degrees plus or minus 0.5 degrees, or 2-theta = 20.1 degrees plus or minus 0.2 degrees.
    [00107] The X-ray diffraction diagrams of crystalline form 3, amorphous form, crystalline form 1 and crystalline form 2 are reported in Figures 1, 2, 3 and 4, respectively. The positions of the X-ray diffraction peaks of crystalline form 3, crystalline form 1 and crystalline form 2 are reported in Tables 2, 3 and 4, respectively. TABLE 2-CRYSTALLINE FORM 3 OF THE COMPOUND OF FORMULA (I)
    TABLE 3-CRYSTALLINE FORM 1 OF THE COMPOUND OF FORMULA (I)
    TABLE 4-CRYSTALLINE FORM 2 OF THE COMPOUND OF FORMULA (I)

    Example 3: Analytical results using Differential Scanning Calorimetry (DSC)
    [00108] DSC analyzes were performed with a Mettler Toledo Star system apparatus. DSC aluminum pans were loaded with 2 to 4 mg of sample. The temperature range of the analyzes was between 25 ° C and a maximum value of 300 ° C. The samples were analyzed under static nitrogen condition at a heating rate of 10 ° C / min.
    [00109] Figure 5 reports DSC thermograms of amorphous form, crystalline form 1 and crystalline form 2.
    [00110] The melting endotherm observed for crystalline form 1 is approximately in the range of 188 ° C to 196 ° C (peak temperature) with Delta H in the range of 54 to 64 J / g. The melting endotherm observed for crystalline form 2 is approximately in the range of 197 ° C to 198.5 ° C (peak temperature) with Delta H in the range of 72 to 78.5 J / g. It will be understood that the appearance and / or temperature values of the DSC peak may vary slightly from one device to another, one method to another or from one sample to another, and therefore the values quoted should not be considered as absolute. In fact, the observed temperatures will depend on the rate of temperature variation, as well as the sample preparation technique and the particular instrument used. It will be estimated and taken into account that the temperature values obtained by applying such different conditions can vary by more or less about 4 ° C. Example 4: Analytical results by means of Dynamic Steam Sorption (DVS)
    [00111] The observed water absorption was investigated by submitting a sample of such substances to a hygroscopicity test using a DVS 1000 (SMS). The device is a "controlled atmosphere microbalance", where the heavy sample is exposed to programmed variations in relative humidity (RH) at a constant and controlled temperature. The measured parameters (weight, time and HR), reported in Excel spreadsheets, allow for obtaining hygroscopicity curves in the tested RH range. For example, sorption / desorption cycles of between 0% and 90% RH can be performed at a controlled temperature of 25 ° C. Progressive HR variations can be, for example, 10% and 3% and are operated by the software to balance the sample weight. This condition can be defined, at a constant percent weight change rate, such as, for example, 0.005% / min.
    [00112] Figure 6 shows the DVS profiles of the amorphous form, crystalline form 1 and crystalline form 2 of the compound of formula (1). The relative humidity values (RH,%) are recorded on the x-axis during the change in mass (%) is reported on the y-axis. The curves are related to the sorption step between 0% RH and 90% RH at 25 ° C.
    [00113] The experimental results show that crystalline form 1 and crystalline form 2 of compound (I) are, respectively, characterized by water absorptions of 0.6% and 0.2% at 25 ° C / 90% RH. Such water absorptions are reversible, lowering the RH at a constant temperature of 25 ° C. Crystalline forms 1 and 2 of compound (I) can be considered of low hygroscopicity.
    [00114] The experimental results also show that the amorphous form of the compound (I) is characterized by a water absorption of 2.5% at 25 ° C / 90% RH, which is reversible, lowering the RH at a constant temperature of 25 ° C. The amorphous form of compound (I) shows higher hygroscopicity than crystalline forms 1 and 2. The water absorption of the amorphous form of compound (I) is higher than crystalline forms 1 and 2. As an additional aspect, the water absorption of the amorphous form of the compound (I) is greater than 1% of the RH values which are less than 30% RH with a subsequent increase in the slope in the region of high RH values. Example 5: Analytical results using Thermogravimetric Analysis (TGA)
    [00115] TGA analyzes were performed with a Perkin-Eimer TGA-7 device. DSC aluminum pans were loaded with 5 to 10 mg of sample. The temperature range of the analyzes was between 30 ° and a maximum value of about 250 ° C. The samples were analyzed under nitrogen flow (to eliminate oxidative and pyrolytic effects) at a heating rate of 2 ° C / min. Example 6: NMR analysis
    [00116] The 1H NMR experiments were performed at a constant temperature of 28 ° C, in a Varian Inova 500 spectrometer for the sample of crystalline form 3 (see Fig. 8) and at a constant temperature of 28 ° C, in a Varian Inova 400 spectrometer for the sample of crystalline form 1 (see Fig. 7). A small amount of each sample was dissolved in 0.75 ml of DMSO-d6 and transferred to a 5 mm NMR tube for subsequent analysis.
    [00117] As the same 1H NMR spectrum is obtained from different crystalline forms, that is, crystalline form 1 and 2 have the same 1H NMR spectrum, only the spectrum of crystalline form 1 is reported. The spectrum of crystalline form 3 is reported only to show the presence of residual solvents, whose signals are clearly distinguished from the product's signals and are highlighted by arrows in Figure 8. Example 7: Percent compositions of a formulation for oral use
    权利要求:
    Claims (10)
    [0001]
    1. Crystalline form 2 of the compound of formula (I),
    [0002]
    2. Pharmaceutical composition, characterized in that it comprises a therapeutically effective amount of a crystalline form 2 as defined in claim 1, as an active ingredient and a pharmaceutically acceptable excipient, carrier or diluent.
    [0003]
    3. Use of crystalline form 2 as defined in claim 1, alone or in combination with other therapeutic agents or radiotherapy, characterized by the fact that it is for the manufacture of a medicine for the treatment of selected cancer disease and cell proliferation disorders.
    [0004]
    4. Use, according to claim 3, characterized by the fact that it is for the manufacture of a medicine, in which said cancer is selected from breast cancer, lung cancer, colorectal cancer, prostate cancer, cancer of ovary, endometrial cancer, gastric cancer, renal clear cell carcinoma, uveal melanoma, multiple myeloma, rhabdomyosarcoma, Ewing's sarcoma, Kaposi's sarcoma, medulloblastoma, glioblastoma, anaplastic large cell lymphoma and neuroblastoma.
    [0005]
    5. Use according to claim 3, characterized by the fact that it is for the manufacture of a medicine. wherein said cancer is non-small cell lung carcinoma.
    [0006]
    6. Use according to claim 3, characterized by the fact that it is for the manufacture of a medication, in which the referred cancer is colorectal cancer.
    [0007]
    7. Process for the preparation of a compound of formula (I)
    [0008]
    Process according to claim 7, characterized in that the compound of formula (II) is suspended in dichloromethane and the compound of formula (III) is suspended in pyridine.
    [0009]
    Process according to claim 14, characterized in that the deprotection of the compound of formula (IV) is carried out in a K2CO3 solution in water / methanol.
    [0010]
    10. Process according to claim 7, characterized in that the amorphous compound of formula (I) is treated sequentially with ethanol at a temperature between 10 ° C and 30 ° C and then with water at a temperature between 10 ° C and 30 ° C.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112014028841B1|2021-01-12|CRYSTALLINE FORMS 1 AND 2, PHARMACEUTICAL COMPOSITION, USE OF CRYSTALLINE 1 FOR THE TREATMENT OF A DISEASE STATABLE BY ALK INHIBITION AND PROCESS FOR THE PREPARATION OF N- [5- | -1H- INDAZOL-3-IL] -4- | -2- | - BENZAMIDE
    WO2017152874A1|2017-09-14|Urea compound, preparation method therefor and medical use thereof
    JP6307088B2|2018-04-04|Quinazolinone and isoquinolinone derivatives
    JP2022031797A|2022-02-22|Solid form of substituted 5,6-dihydro-6-phenylbenzo [F] isoquinoline-2-amine compound
    US9453011B2|2016-09-27|Crystal form of dabrafenib mesylate and preparation method thereof
    JP4519114B2|2010-08-04|Solid salt form of pyrrole-substituted 2-indolinone
    TW201125861A|2011-08-01|CDC7 inhibitor salts
    TW201829398A|2018-08-16|Protein tyrosine kinase modulators salt, crystallographic forms, and uses thereof
    US20220048914A1|2022-02-17|Preparation for 6-amino-1h-pyrazolo[3,4-d]pyrimidine-based jak kinase inhibitor and application thereof
    WO2013159698A1|2013-10-31|Fused ring quinazoline hydroximic acid compound and use thereof as anti-tumour drug
    同族专利:
    公开号 | 公开日
    BR112014028841A2|2017-06-27|
    IL235761D0|2015-02-01|
    US9649306B2|2017-05-16|
    NZ703124A|2016-07-29|
    CA2873979A1|2013-11-28|
    US9382235B2|2016-07-05|
    JP6231556B2|2017-11-15|
    IL235761A|2018-07-31|
    KR102151963B1|2020-09-07|
    PL3333166T3|2020-09-07|
    AR091138A1|2015-01-14|
    JP2015517551A|2015-06-22|
    EP3333166B1|2019-11-06|
    EP2855460A1|2015-04-08|
    KR20150016352A|2015-02-11|
    CN104395308A|2015-03-04|
    ES2771100T3|2020-07-06|
    EP2855460B1|2017-11-08|
    TWI579280B|2017-04-21|
    CN104395308B|2016-08-24|
    US20150051222A1|2015-02-19|
    EP3581571A1|2019-12-18|
    US20160279125A1|2016-09-29|
    RU2602071C2|2016-11-10|
    EP3290414A1|2018-03-07|
    AU2018201037A1|2018-03-01|
    IL260297D0|2018-08-30|
    MX2014013924A|2015-02-17|
    RU2014151565A|2016-07-20|
    AU2013265288A2|2015-01-29|
    WO2013174876A1|2013-11-28|
    EP3290414B1|2019-07-24|
    US9085565B2|2015-07-21|
    AU2013265288B2|2017-12-21|
    HK1207077A1|2016-01-22|
    PL3290414T3|2020-01-31|
    NZ716487A|2017-01-27|
    ES2751944T3|2020-04-02|
    CN106167485A|2016-11-30|
    TW201400479A|2014-01-01|
    CA2873979C|2019-11-12|
    EP3333166A1|2018-06-13|
    AU2013265288A1|2015-01-22|
    AU2018201037B2|2019-07-04|
    US20150274707A1|2015-10-01|
    MX355409B|2018-04-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    FI58125C|1976-12-15|1985-01-02|Orion Yhtymae Oy|PROCEDURE FOR FRAMSTATING AV 6,7-DIMETOXY-4-AMINO-2- -1-PIPERAZINYL) QUINAZOLINE WITH BLODTRYCKSSAENKANDE VEKAN|
    DE19730989A1|1997-07-18|1999-01-21|Merck Patent Gmbh|Piperazine derivatives|
    MX2009006401A|2006-12-20|2009-06-23|Nerviano Medical Sciences Srl|Indazole derivatives as kinase inhibitors for the treatment of cancer.|
    EA018503B1|2007-07-20|2013-08-30|НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.|Substituted indazole derivatives active as kinase inhibitors|
    JP5580332B2|2008-12-18|2014-08-27|ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ|Substituted indazole derivatives active as kinase inhibitors|
    TWI579280B|2012-05-23|2017-04-21|內維亞諾醫學公司|Process for the preparation of n-[5--1h-indazol-3-yl]-4--2--benzamide|EA018503B1|2007-07-20|2013-08-30|НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.|Substituted indazole derivatives active as kinase inhibitors|
    PT2350075E|2008-09-22|2014-06-09|Array Biopharma Inc|Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors|
    ES2669581T7|2008-10-22|2020-07-29|Array Biopharma Inc|Pyrazolo [1,5-a] pyrimidine compounds as TRK kinase inhibitors|
    AR077468A1|2009-07-09|2011-08-31|Array Biopharma Inc|PIRAZOLO COMPOUNDSPYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS|
    CR20170098A|2010-05-20|2017-07-17|Array Biopharma Inc|MACROCICLICAL COMPOUNDS AS QUINASA TRK INHIBITORS|
    TWI579280B|2012-05-23|2017-04-21|內維亞諾醫學公司|Process for the preparation of n-[5--1h-indazol-3-yl]-4--2--benzamide|
    WO2015017533A1|2013-07-30|2015-02-05|Blueprint Medicines Corporation|Ntrk2 fusions|
    US10231965B2|2014-02-20|2019-03-19|Ignyta, Inc.|Molecules for administration to ROS1 mutant cancer cells|
    CN113354649A|2014-11-16|2021-09-07|阵列生物制药公司|Novel crystal form|
    EP3227276B1|2014-12-02|2021-09-01|Ignyta, Inc.|Combinations for the treatment of neuroblastoma|
    WO2016089853A1|2014-12-03|2016-06-09|Ignyta, Inc.|Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer|
    CA2988423A1|2015-06-01|2016-12-08|Loxo Oncology, Inc.|Methods of diagnosing and treating cancer|
    KR20180041135A|2015-07-16|2018-04-23|어레이 바이오파마 인크.|A pyrazolo [1,5-a] pyridine compound substituted as a RET kinase inhibitor|
    RU2744852C2|2015-10-26|2021-03-16|Локсо Онколоджи, Инк.|Point mutations in trk inhibitor-resistant malignant tumors and related methods|
    AU2016370846A1|2015-12-18|2018-07-05|Ignyta, Inc.|Combinations for the treatment of cancer|
    US10045991B2|2016-04-04|2018-08-14|Loxo Oncology, Inc.|Methods of treating pediatric cancers|
    TN2018000335A1|2016-04-04|2020-01-16|Loxo Oncology Inc|Liquid formulations of -n--2--pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide|
    WO2017176744A1|2016-04-04|2017-10-12|Loxo Oncology, Inc.|Methods of treating pediatric cancers|
    PL3458456T3|2016-05-18|2021-04-19|Loxo Oncology, Inc.|Preparation of -n--2-pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide|
    AU2017271458B2|2016-05-24|2020-11-26|Nerviano Medical Sciences S.R.L.|New crystalline form of N-[5--1H-indazol-3-yl]-4--2--benzamide|
    TWI704148B|2016-10-10|2020-09-11|美商亞雷生物製藥股份有限公司|Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors|
    CR20190224A|2016-10-10|2019-09-30|Array Biopharma Inc|Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors|
    MA45802A1|2017-06-26|2019-12-31|Loxo Oncology Inc|Process for the preparation of pyrazolo [1,5-a] pyrimidines and salts thereof|
    WO2018136661A1|2017-01-18|2018-07-26|Andrews Steven W|SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS|
    WO2018136663A1|2017-01-18|2018-07-26|Array Biopharma, Inc.|Ret inhibitors|
    TN2019000263A1|2017-03-16|2021-01-07|Array Biopharma Inc|Macrocyclic compounds as ros1 kinase inhibitors|
    WO2019018570A1|2017-07-19|2019-01-24|Ignyta, Inc.|Pharmaceutical compositions comprising entrectinib|
    TW201922741A|2017-10-10|2019-06-16|美商亞雷生物製藥股份有限公司|Crystalline forms|
    TW201922252A|2017-10-10|2019-06-16|美商絡速藥業公司|Formulations of 6--4-methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile|
    WO2019077506A1|2017-10-17|2019-04-25|Ignyta, Inc.|Pharmaceutical compositions and dosage forms|
    EP3700576A1|2017-10-26|2020-09-02|Array Biopharma Inc.|Formulations of a macrocyclic trk kinase inhibitor|
    CA3087354A1|2018-01-18|2019-07-25|Array Biopharma Inc.|Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors|
    US20200339579A1|2018-01-18|2020-10-29|Array Biopharma Inc.|Substituted pyrazolyl[4,3-c]pyridine compounds as ret kinase inhibitors|
    WO2019191659A1|2018-03-29|2019-10-03|Loxo Oncology, Inc.|Treatment of trk-associated cancers|
    CA3108065A1|2018-07-31|2020-02-06|Loxo Oncology, Inc.|Spray-dried dispersions and formulations of -5-amino-3-methyl)phenyl)-1--1h-pyrazole-4-carboxamide|
    JP2022500383A|2018-09-10|2022-01-04|アレイ バイオファーマ インコーポレイテッド|Condensed heterocyclic compound as a RET kinase inhibitor|
    US20220041579A1|2018-12-19|2022-02-10|Array Biopharma Inc.|Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases|
    CN113490666A|2018-12-19|2021-10-08|奥瑞生物药品公司|Substituted pyrazolo [1,5-A ] pyridine compounds as inhibitors of FGFR tyrosine kinases|
    WO2021018928A1|2019-07-31|2021-02-04|F. Hoffmann-La Roche Ag|New pharmaceutical formulation|
    WO2021084260A1|2019-11-01|2021-05-06|Johnson Matthey Public Limited Company|Crystalline entrectinib anhydrate and monohydrate forms; crystalline entrectinib thf, nitromethane, isopropyl acetate and methanol solvate forms; processes for preparing a crystalline entrectinib anhydrate form|
    CN111171009A|2020-01-10|2020-05-19|安礼特（上海）医药科技有限公司|Entrictinib crystal form and preparation method thereof|
    法律状态:
    2018-01-16| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|
    2018-03-06| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2018-03-13| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2018-03-20| B06I| Publication of requirement cancelled [chapter 6.9 patent gazette]|Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
    2019-12-17| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2019-12-24| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2020-06-23| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|
    2020-12-08| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-01-12| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/05/2013, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    EP12169139|2012-05-23|
    EP12169139.8|2012-05-23|
    PCT/EP2013/060534|WO2013174876A1|2012-05-23|2013-05-22|Process for the preparation of n-[5--1h-indazol-3-yl]-4--2--benzamide|
    [返回顶部]